Fig. 7: Pifithrin-μ potentiates sorafenib sensitivity of mTOR-activated primary liver tumor.
From: Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment
A, B Tumor formation of 8-month-old mice. Representative liver images (A), liver tissue staining of H&E, Heppar1, and CK19, scale bar = 100 μm (B). C–H Liver tumors in Tsc2−/− mice at 8 months. Mice were treated with vehicle, pifithrin-μ (10 mg/kg, i.p.), sorafenib (20 mg/kg, i.g.), or combined pifithrin-μ (10 mg/kg, i.p.) and sorafenib (20 mg/kg, i.g.) every other day (n = 8 per group) for 2 months. Schematic depiction of treatment schedules (C), representative liver images (D), liver tissue staining of H&E and Ki67, scale bar = 100 μm (E), serum ALT levels (F), serum AST levels (G), and immunoblotting (H). Data are displayed as mean ± SD (error bars). **p < 0.01, ***p < 0.001. PES pifithrin-μ, Sora sorafenib.
